United Kingdom · Delayed Price · Currency is GBP · Price in GBX AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 209.51 billion. The enterprise value is 229.28 billion.
| Market Cap | 209.51B |
| Enterprise Value | 229.28B |
Important Dates
The last earnings date was Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 6, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 74.12% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 25.40 and the forward PE ratio is 17.08. AstraZeneca's PEG ratio is 1.41.
| PE Ratio | 25.40 |
| Forward PE | 17.08 |
| PS Ratio | 4.63 |
| PB Ratio | 5.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.32 |
| P/OCF Ratio | 21.85 |
| PEG Ratio | 1.41 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.57, with an EV/FCF ratio of 30.89.
| EV / Earnings | 28.59 |
| EV / Sales | 5.06 |
| EV / EBITDA | 14.57 |
| EV / EBIT | 19.64 |
| EV / FCF | 30.89 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.66.
| Current Ratio | 1.01 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 3.36 |
| Interest Coverage | 11.05 |
Financial Efficiency
Return on equity (ROE) is 22.57% and return on invested capital (ROIC) is 17.15%.
| Return on Equity (ROE) | 22.57% |
| Return on Assets (ROA) | 8.58% |
| Return on Invested Capital (ROIC) | 17.15% |
| Return on Capital Employed (ROCE) | 18.16% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | 488,965 |
| Profits Per Employee | 86,453 |
| Employee Count | 96,100 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, AstraZeneca has paid 1.71 billion in taxes.
| Income Tax | 1.71B |
| Effective Tax Rate | 17.04% |
Stock Price Statistics
The stock price has increased by +8.63% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +8.63% |
| 50-Day Moving Average | 12,468.00 |
| 200-Day Moving Average | 13,429.89 |
| Relative Strength Index (RSI) | 59.83 |
| Average Volume (20 Days) | 2,656,014 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 46.99 billion and earned 8.31 billion in profits. Earnings per share was 5.32.
| Revenue | 46.99B |
| Gross Profit | 38.43B |
| Operating Income | 12.12B |
| Pretax Income | 10.02B |
| Net Income | 8.31B |
| EBITDA | 16.03B |
| EBIT | 12.12B |
| Earnings Per Share (EPS) | 5.32 |
Balance Sheet
The company has 6.15 billion in cash and 25.85 billion in debt, with a net cash position of -19.70 billion or -12.70 per share.
| Cash & Cash Equivalents | 6.15B |
| Total Debt | 25.85B |
| Net Cash | -19.70B |
| Net Cash Per Share | -12.70 |
| Equity (Book Value) | 39.03B |
| Book Value Per Share | 25.12 |
| Working Capital | 136.33M |
Cash Flow
In the last 12 months, operating cash flow was 9.97 billion and capital expenditures -2.28 billion, giving a free cash flow of 7.69 billion.
| Operating Cash Flow | 9.97B |
| Capital Expenditures | -2.28B |
| Depreciation & Amortization | 3.86B |
| Net Borrowing | 420.10M |
| Free Cash Flow | 7.69B |
| FCF Per Share | 4.96 |
Margins
Gross margin is 81.78%, with operating and profit margins of 25.80% and 17.68%.
| Gross Margin | 81.78% |
| Operating Margin | 25.80% |
| Pretax Margin | 21.32% |
| Profit Margin | 17.68% |
| EBITDA Margin | 34.11% |
| EBIT Margin | 25.80% |
| FCF Margin | 16.55% |
Dividends & Yields
This stock pays an annual dividend of 2.39, which amounts to a dividend yield of 1.77%.
| Dividend Per Share | 2.39 |
| Dividend Yield | 1.77% |
| Dividend Growth (YoY) | -2.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 43.82% |
| FCF Payout Ratio | 48.20% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 1.72% |
| Earnings Yield | 3.94% |
| FCF Yield | 3.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for AstraZeneca is 15,927.74, which is 17.91% higher than the current price. The consensus rating is "Buy".
| Price Target | 15,927.74 |
| Price Target Difference | 17.91% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 6.76% |
| EPS Growth Forecast (3Y) | 11.11% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.6 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 6 |